Psyadon Pharmaceuticals Inc.

Emalex Biosciences Inc. significantly expanded on its previous capacity to fund the upcoming Phase III clinical trial of ecopipam in Tourette’s syndrome with a $250m series D financing barely a year

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held

Teva Pharmaceutical Industries Ltd. ’s attempts to add a “meaningful” additional market for one of its newer specialty brands, Austedo, have hit the buffers after two late-stage studies failed to show

Tourette syndrome is proving a difficult disorder to crack by pharmacological means. US biotech Neurocrine Biosciences Inc. has again reported disappointing early-stage clinical results in the disor